Urticaria

FDA application is based on the positive data from 3 recent phase 3 clinical trials.

Only 29.5% of sampled CBD users claimed any wellness benefit.

Many patients do not see meaningful improvement with the current standard treatment. New data suggest this monoclonal antibody might be a better choice.

A higher proportion of risankizumab users achieved improved measures for symptoms, quality of life, and mental health versus comparators.

Though atopic dermatitis is a relatively common condition, most of the existing scientific literature has ignored the majority of patients who have mild or limited disease.

About 69% of patients with CIU were either obese or overweight, and experienced a longer duration of disease than those who had lower weight values.

New research suggests the Janus kinase 1 and 2 inhibitor relieves symptoms of atopic dermatitis at a daily dose of 4 mg.

Newly published data show routine testing is unlikely to change the management of patients with CSU.

Both antihistamines are indicated for treatment of chronic idiopathic urticaria, yet olopatadine demonstrates better clinical improvements and fewer adverse events.

Patients impacted by pruritus were more depressed and anxious than a comparison control group.

More studies are needed on the effectiveness and safety of plaque psoriasis therapies for older patients.

More trials must include older patients in order to better understand the safety and efficacy of systemic treatments for atopic dermatitis.

The study addresses safety concerns related to the risk of keratinocyte carcinoma for patients with atopic dermatitis.

Older, white patients and those who use linagliptin are at a higher risk of bullous pemphigoid.

A new phase 2b trial shows the investigative therapy significantly improves the rate of patients with hives control over 12 weeks versus its competitor.